Cargando...
Predictors of availability of long-acting medication for opioid use disorder
BACKGROUND: The U.S. Food and Drug Administration has approved three long-acting medications for opioid use disorder (MOUD): extended-release naltrexone (XR-NTX) in 2010, a subdermal buprenorphine implant in 2016, and a depot buprenorphine injection in 2017. Long-acting MOUD options may improve adhe...
Gardado en:
| Publicado en: | Drug Alcohol Depend |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6910228/ https://ncbi.nlm.nih.gov/pubmed/31593871 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.drugalcdep.2019.107586 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|